Results 171 to 180 of about 5,279 (205)

Inequity in Paxlovid Prescribing

JAMA, 2022
openaire   +2 more sources

Paxlovid Expiration Dates Extended

JAMA, 2022
openaire   +2 more sources

A Television Interview with Paxlovid

Daxue Huaxue, 2022
Minghong Yang, Hongjian Lu, Zhen Shen, Kin Shing Chan   +3 more
openaire   +1 more source

Safety Profile of Paxlovid in the Treatment of COVID-19

Current Pharmaceutical Design
Background: With the urgent and widespread application of Paxlovid, a novel antiviral drug for Coronavirus Disease 2019 (COVID-19) in clinical practice, concerns regarding its actual efficacy and safety have emerged. In order to provide more evidence to support its clinical application, we sought to perform a descriptive analysis of cases who ...
Bing Lv, Xin Gao, Guoqiang Zeng, Hui Guo, Faping Li   +4 more
openaire   +2 more sources

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.

Clinical Infectious Diseases, 2023
Ronza Najjar-Debbiny, Gabriel Weber
exaly  

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis

Annals of Medicine, 2022
Mingwei W, Feng Zhanhui, Jiake Tang
exaly  

Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study

The Lancet Regional Health - Western Pacific, 2023
Dechang Chen, Zhenliang Wen, Sisi Huang
exaly  

Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis

Journal of Medical Virology, 2023
Bahman Amani, Behnam Amani
exaly  

Paxlovid for hospitalized COVID-19 patients with chronic kidney disease

Antiviral Research, 2023
Mingli Zhu, Jiayue Lu, Zhenyuan Li
exaly  

Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid™ therapy

Future Virology, 2022
Petri T Kovanen, Alpo Vuorio, Frederick J Raal   +2 more
exaly